# Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy

> **NCT00919711** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 870 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Actonel®
- **DRUG:** Denosumab

## Key facts

- **NCT ID:** NCT00919711
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-01
- **Primary completion:** 2011-12-21
- **Final completion:** 2012-03-05
- **Target enrollment:** 870 (ACTUAL)
- **Last updated:** 2020-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00919711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00919711, "Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00919711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*